Impact of HbA1c, Followed From Onset of Type 1 Diabetes, on the Development of Severe Retinopathy and Nephropathy: The VISS Study (Vascular Diabetic Complications in Southeast Sweden)
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: HbA1c is strongly related to the development of diabetes complications, but it is still controversial which HbA1c level to strive for in the treatment of type 1 diabetes. The aim of the current study was to evaluate HbA1c, followed from diagnosis, as a predictor of severe microvascular complications and to formulate HbA1c target levels for treatment. RESEARCH DESIGN AND METHODS: A longitudinal observation study followed an unselected population of 451 patients diagnosed with type 1 diabetes during 1983–1987 before the age of 35 years in a region of Southeast Sweden. Retinopathy was evaluated by fundus photography and nephropathy data collected from medical records. HbA1c was measured starting from diagnosis and during the whole follow-up period of 20–24 years. Long-term weighted mean HbA1c was then calculated. Complications were analyzed in relation to HbA1c levels. RESULTS: The incidence of proliferative retinopathy and persistent macroalbuminuria increased sharply and occurred earlier with increasing long-term mean HbA1c. None of the 451 patients developed proliferative retinopathy or persistent macroalbuminuria below long-term weighted mean HbA1c 7.6% (60 mmol/mol); 51% of the patients with long-term mean HbA1c above 9.5% (80 mmol/mol) developed proliferative retinopathy and 23% persistent macroalbuminuria. CONCLUSIONS: Long-term weighted mean HbA1c, measured from diagnosis, is closely associated with the development of severe complications in type 1 diabetes. Keeping HbA1c below 7.6% (60 mmol/mol) as a treatment target seems to prevent proliferative retinopathy and persistent macroalbuminuria for up to 20 years.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, the CKD-EPI equation has been updated to a new version that is race agnostic and termed CKD-EPI 2021.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [396]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Analysis of serial measurements in medical research.
Matthews, J. N., Altman, D. G., Campbell, M. J., & Royston, P. (1990) · BMJ · doi:10.1136/bmj.300.6719.230 · Cited by 3,136
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study
Andersen, A. R., Christiansen, J. S., Andersen, J. K., Kreiner, S., & Deckert, T. (1983) · Diabetologia · doi:10.1007/bf00284458 · Cited by 1,067
The Glycosylation of Hemoglobin: Relevance to Diabetes Mellitus
Bunn, H. F., Gabbay, K. H., & Gallop, P. M. (1978) · Science · doi:10.1126/science.635569 · Cited by 876
Renal and retinal effects of enalapril and losartan in type 1 diabetes
Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808400 · Cited by 791
Hoelzel, W., Weykamp, C., Jeppsson, J.-O., Miedema, K., Barr, J. R., Goodall, I., Hoshino, T., John, W. G., Kobold, U., Little, R., et al. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.024802 · Cited by 690
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
Diabetes Control and Complications Trial (DCCT) Research Group (1996) · Diabetes · doi:10.2337/diab.45.10.1289 · Cited by 597
Research works printed but not linked: 1
- 2007, Diabetes Care
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence
Simó, R., & Hernández, C. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.04.003 · Cited by 239
“6% (60 mmol/mol) as a treatment target seems to prevent PDR for up to 20 years in type 1 diabetic patients (Nordwall et al., 2015).”
BackgroundInfluentialDiabetic Retinopathy in the Context of Patients with Diabetes
Simó-Servat, O., Hernández, C., & Simó, R. (2019) · Ophthalmic Research · doi:10.1159/000499541 · Cited by 233
Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: Future Therapies
Rodríguez, M. L., Pérez, S., Mena-Mollá, S., Desco, M. C., & Ortega, Á. L. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/4940825 · Cited by 222
“6% (60mmol/mol), it seems to prevent proliferative DR for up to 20 years in T1DM patients [24].”
BackgroundLind, M., Pivodic, A., Svensson, A.-M., Ólafsdóttir, A. F., Wedel, H., & Ludvigsson, J. (2019) · BMJ · doi:10.1136/bmj.l4894 · Cited by 175
Self-citationPieber, T. R., Famulla, S., Eilbracht, J., Cescutti, J., Soleymanlou, N., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Kaspers, S. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12494 · Cited by 166
(2023) · doi:10.1002/14651858.cd013775.pub2 · Cited by 145
Diabetes microvascular complications—A clinical update
Khalil, H. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.12.022 · Cited by 147
“This is consistent with the latest Vascular Diabetic Complications in Southeast Sweden (VISS) study [26].”
BackgroundResultInfluentialWang, L., Yang, H., Huang, H., Zhang, C., Zuo, H.-X., Xu, P., Niu, Y.-M., & Wu, S.-S. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-02159-0 · Cited by 118
The trials and tribulations of determining HbA1c targets for diabetes mellitus
Klein, K. R., & Buse, J. B. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00425-6 · Cited by 97
REDONDO, M. J., Libman, I. M., Maahs, D. M., Lyons, S. K., Saraco, M., Reusch, J. E. B., Rodriguez, H., & DiMeglio, L. A. (2021) · Diabetes Care · doi:10.2337/dc20-1978 · Cited by 95
Groop, P.-H., Dandona, P., Phillip, M., Gillard, P., Edelman, S., Jendle, J., Xu, J., Scheerer, M. F., Thoren, F., Iqbal, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30280-1 · Cited by 79
Jiao, X., Shen, Y., & Chen, Y. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002633 · Cited by 76
“32 33 This study showed that CLS has better HbA1c levels, suggesting that the use of CLS in T1DM Figure 4 Forest plot of differences in sensor glucose metrics between CLS versus control, presented by time of day (24 hours, night, day).”
Reaven, P. D., Newell, M., Rivas, S., Zhou, X., Norman, G. J., & Zhou, J. (2023) · Diabetes Care · doi:10.2337/dc22-2189 · Cited by 79
Lu, X., & Zhao, C. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1792-1_7 · Cited by 91
Chronic conditions in adolescents
Jin, M., An, Q., & Wang, L. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4526 · Cited by 65
Molecular and biochemical trajectories from diabetes to Alzheimer’s disease: A critical appraisal
Sandhir, R., & Gupta, S. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i12.1223 · Cited by 49
Physical Activity Levels of Adolescents with Type 1 Diabetes Physical Activity in T1D
de Lima, V. A., Mascarenhas, L. P. G., Decimo, J. P., de Souza, W. C., Monteiro, A. L. S., Lahart, I. M., Nesi-França, S., & Leite, N. (2017) · Pediatric Exercise Science · doi:10.1123/pes.2016-0199 · Cited by 55
Ying, C., Zhou, X., Chang, Z., Ling, H., Cheng, X., & Li, W. (2016) · Endocrine · doi:10.1007/s12020-016-0867-z · Cited by 46
Zaitcev, A., Eissa, M. R., Zheng, H., Good, T., Elliott, D., & Benaissa, M. (2020) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2020.2967546 · Cited by 54
“It has been clinically shown that lower HbA1c levels (below 59 mmol/mol) are associated with significantly smaller risks of serious diabetes-related complications such as retinopathy (eye damage) nephropathy (kidney damage) and nerve damage (neuropathy) [3].”
BackgroundKhanolkar, A. R., Amin, R., Taylor‐Robinson, D., Viner, R. M., Warner, J. T., & Stephenson, T. (2016) · Diabetic Medicine · doi:10.1111/dme.13079 · Cited by 42
Forga, L., Goñi, M. J., Ibáñez, B., Cambra, K., Mouriz, M. G., & Iriarte, A. (2016) · Journal of Diabetes Research · doi:10.1155/2016/9898309 · Cited by 41
“publications based on national or regional T1D records, some of them recently [1, 18].”
BackgroundArnqvist, H. J., Westerlund, M. C., Fredrikson, M. G., Ludvigsson, J., & Nordwall, M. (2022) · Diabetes Care · doi:10.2337/dc22-0239 · Cited by 43
Self-citationRamanathan, A. S. (2017) · Integrative Molecular Medicine · doi:10.15761/imm.1000272 · Cited by 44
“6% was beneficial in preventing retinopathy and persistent microalbuminuria for up to 20 years [21].”
BackgroundResultLow carbohydrate high fat ketogenic diets on the exercise crossover point and glucose homeostasis
Noakes, T. D., Prins, P. J., Volek, J. S., D’Agostino, D. P., & Koutnik, A. P. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1150265 · Cited by 33
“While the exact consequences of these prediabetic glucose values in populations regularly engaging in physical activity requires additional analyses, and additional confirmation is warranted, it appears unlikely that persistent and elevated glucose values would be recommended granted the demonstrated adverse effects o…”
BackgroundDost, A., Pozza, S. B., Bollow, E., Kovacic, R., Vogel, P., Feldhahn, L., Schwab, K.-O., Holl, R. W., & for the Initiative, D. P. V. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12502 · Cited by 33
“Our data rather relate to the findings of the VISS study of southeastern Sweden with a rate of 15% MA after 20 years of follow up in T1DM patients.(26) In our patients, MA was related to increased BP but not to nocturnal PP, supporting earlier reports of Lurbe et al and Darcan et al.”
BackgroundResultInfluentialda Rosa, L. C. G. F., Zajdenverg, L., Souto, D. L., Dantas, J. R., Pinto, M. V., de Salles, G. F. D. C. M., & Rodacki, M. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.05.022 · Cited by 34
Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2
Nowak, C., Lind, M., Šumník, Z., Pelikánová, T., Nattero‐Chávez, L., Lundberg, E., Rica, I., Martínez‐Brocca, M. A., de Adana, M. R., Wahlberg, J., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac343 · Cited by 39
“Glycated hemoglobin (HbA1c) is associated with diabetes complications including cardiovascular disease and mortality (5-7) and is an accepted surrogate endpoint in clinical trials.”
BackgroundSelf-citationBjerg, L., Hulmán, Á., Carstensen, B., Charles, M., Jørgensen, M. E., & Witte, D. R. (2018) · Diabetes Care · doi:10.2337/dc18-0679 · Cited by 40
“complications are HbA1c and duration of diabetes (17,20,29), but metabolic risk factors, other vascular complications, and various metabolic pathways also may play a role (30–32).”
BackgroundCordelli, E., Maulucci, G., Spirito, M. D., Rizzi, A., Pitocco, D., & Soda, P. (2018) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2018.05.025 · Cited by 35
Zhang, L., Wang, M., Zhang, R., Zhong, Y., Fan, H., Wang, M., & Wang, J. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107673 · Cited by 31
Frudd, K., Sivaprasad, S., Raman, R., Krishnakumar, S., Revathy, Y. R., & Turowski, P. (2021) · Acta Ophthalmologica · doi:10.1111/aos.14954 · Cited by 36
Heterogeneity of glycaemic phenotypes in type 1 diabetes
Fagherazzi, G., Aguayo, G., Zhang, L., Hanaire, H. P., Picard, S., Sablone, L., Vergès, B. L., Hamamouche, N., Detournay, B., Joubert, M., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06179-4 · Cited by 33
“HbA 1c has been correlated with chronic complications [2, 3], but other aspects of glycaemic control have also been associated with these complications, such as glucose variability and hypoglycaemia [4].”
Nylander, C., Tindberg, Y., Haas, J., Swenne, I., Torbjörnsdotter, T., Åkesson, K., Örtqvist, E., Gustafsson, J., & Fernell, E. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12520 · Cited by 32
“HbA1c exceeding 70 mmol/mol has been correlated to other long-term complications, such as cardiovascular disease and nephropathy(27) while HbA1c below 60 mmol/mol has been associated with a low risk for these complications.(28)”
BackgroundMaulucci, G., Cordelli, E., Rizzi, A., Leva, F. D., Papi, M., Ciasca, G., Samengo, D., Pani, G., Pitocco, D., Soda, P., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184109 · Cited by 30
Vieira, M. B., Neves, J. S., Leitão, L., Baptista, R. B., Magriço, R., Dias, C. V., Oliveira, A. B. F. D., Carvalho, D. M., & Causland, F. R. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00073 · Cited by 28
Rathsman, B., Haas, J., Persson, M., Ludvigsson, J., Svensson, A. ‐., Lind, M., Franko, M. A., & Nyström, T. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13212 · Cited by 31
Self-citationNordwall, M., Fredriksson, M. G., Ludvigsson, J., & Arnqvist, H. J. (2019) · Diabetes Care · doi:10.2337/dc18-1950 · Cited by 24
Self-citationTyrberg, M., Nyström, L., Arnqvist, H. J., Bolinder, J., Guðbjörnsdóttir, S., Landin‐Olsson, M., Eriksson, J. W., & Svensson, M. K. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.08.009 · Cited by 27
“In the Vascular Diabetic Complications in Southeast Sweden study (VISS), where patients with T1D diagnosed during 1983–1987 were followed 20–24 years it was suggested that a HbA1c below 60 mmol/mol could be a ‘‘safe level” [30].”
BackgroundSelf-citationGutefeldt, K., Hedman, C. A., Thyberg, I. S. M., Bachrach‐Lindström, M., Arnqvist, H. J., & Spångéus, A. (2017) · Disability and Rehabilitation · doi:10.1080/09638288.2017.1397202 · Cited by 23
“In our study, microangiopathy was indirectly assessed by asking the patients about previous laser-treated retinopathy, a measure of severe retinopathy [28].”
Self-citationon the behalf of the DISS Study group, Samuelsson, M., Dereke, J., Svensson, M. K. E., Landin‐Olsson, M., & Hillman, M. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0240-2 · Cited by 23
“Previous studies have found significantly higher HbA1c levels in patients developing long-term complications such as DN when measuring long term mean HbA1c from onset of diabetes, or at the time of onset of DN [34, 37, 38].”
BackgroundMellor, J., Jeyam, A., Beulens, J. W. J., Bhandari, S., Broadhead, G., Chew, E. Y., Fickweiler, W., van der Heijden, A. A. W. A., Gordin, D., Simó, R., et al. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100494 · Cited by 25
“41 There is no information regarding the long-term effect of blood glucose control on retinal neurodysfunction or neurodegeneration.”
The clinical potential of low-level C-peptide secretion
Ludvigsson, J. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1210513 · Cited by 20
Self-citationOtani, T., Yokoyama, H., Ohashi, Y., & Uchigata, Y. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000177 · Cited by 18
“16 The better glycemic control is likely brought about by the advancements in treatment.”
BackgroundDesign Considerations for Artificial Pancreas Pivotal Studies
Russell, S. J., & Beck, R. W. (2015) · Diabetes Care · doi:10.2337/dc15-2449 · Cited by 18
“the reduction in complications associated with further lowering of HbA1c below 7% (53 mmol/mol) is low in absolute terms (12,13) and consistent control at a higher level of HbA1c may be sufficient to prevent microvascular complications (14).”
BackgroundPinto, M. V., da Rosa, L. C. G. F., Pinto, L. F., Dantas, J. R., Salles, G. F., Zajdenverg, L., Rodacki, M., & Lima, M. A. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00594-4 · Cited by 21
Artificial Pancreas or Novel Beta-Cell Replacement Therapies: a Race for Optimal Glycemic Control?
Nijhoff, M. F., & de Koning, E. J. P. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1073-6 · Cited by 20
de Bock, M. I., Jones, T. W., Fairchild, J. M., Mouat, F., & Jefferies, C. (2018) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.14122 · Cited by 18
Thorstensson, S., Fröden, M., Vikström, V., & Andersson, S. (2015) · Nordic journal of nursing research · doi:10.1177/0107408315615020 · Cited by 25
“0mmol/L to prevent or postpone severe complications.(5,6) Intensified insulin treatment leads to reduced long-term complications such as microvascular complications of T1D(7,8) as well as increased well-being without adverse effects.”
BackgroundPrevention of Vascular Complications in Diabetes Mellitus Patients: Focus on the Arterial Wall
Lunder, M., Janić, M., & Šabović, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180206113755 · Cited by 21
Effect of COVID‐19 pandemic on treatment of Type 1 diabetes in children
Ludvigsson, J. (2020) · Acta Paediatrica · doi:10.1111/apa.15627 · Cited by 15
Self-citationKaku, K., Isaka, H., Sakatani, T., & Toyoshima, J. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13181 · Cited by 14
Glycemic control and complications of type 1 diabetes among children in Tanzania
Najem, S., Majaliwa, E. S., Ramaiya, K. L., Swai, A. B. M., Jasem, D., & Ludvigsson, J. (2020) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2020.100245 · Cited by 15
Self-citationGloaguen, E., Bendelac, N., Nicolino, M. P., Julier, C., & Mathieu, F. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3051 · Cited by 20
HemoglobinA1c Is a Risk Factor for Changes of Bone Mineral Density: A Mendelian Randomization Study
Ji, X., Hong, J., Qu, Z., Yang, W., Wang, Y., Lin, J., Li, C., Wang, J., Mou, H., Shi, M., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.942878 · Cited by 18
“It indicates that controlling HbA1c levels can prevent proliferative retinopathy and persistent macroalbuminuria for up to 20 years (33).”
BackgroundHaghighatpanah, M. A., Thunga, G., Khare, S., & Mallayasamy, S. (2016) · International Journal of Pharmacy and Pharmaceutical Sciences · Cited by 18
Jonusas, J., Aleknavičius, K., & Valinskas, S. (2023) · Smart Health · doi:10.1016/j.smhl.2023.100404 · Cited by 13
Epidemiología en la diabetes tipo 1: ayudando a encajar las piezas del puzle
Forga, L. (2015) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2015.02.002 · Cited by 35
de Bock, M. I., McAuley, S. A., Abraham, M. B., Smith, G. J., Nicholas, J. A., Ambler, G. R., Cameron, F. J., Fairchild, J. M., King, B. R., Geelhoed, E. A., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020275 · Cited by 15
“Long-term poor control is known to predict the development of diabetes complications.(5) However, despite improvements in diabetes education, insulin pharmacology, glucose monitoring and insulin delivery devices, fewer than a third of patients reach haemoglobin A1c (HbA1c) targets set by international guidelines.”
BackgroundKofod, D. H., Carlson, N., Almdal, T., Bomholt, T., Torp-Pedersen, C., Nørgaard, K., Svendsen, J. H., Feldt‐Rasmussen, B., & Hornum, M. (2025) · Diabetes Care · doi:10.2337/dc25-0339 · Cited by 17
HbA1clevels in children with type 1 diabetes and correlation to diabetic retinopathy
Andreasson, R., Ekelund, C., Landin‐Olsson, M., & Nilsson, C. (2018) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2017-0417 · Cited by 21
Metabolic memory and diabetic retinopathy: Legacy of glycemia and possible steps into future
Sheemar, A., Bellala, K., Sharma, S. V., Sharma, S., Kaur, I., Rani, P. K., Sivaprasad, S., Narayan, K. M. V., Das, T., & Takkar, B. (2024) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2563_23 · Cited by 13
“[62] It was a longitudinal observational study that recruited 451 people with early T1DM diagnosed before age 35 and followed up for a mean of 22 years.”
BackgroundMassarenti, L., Aniol-Nielsen, C., Enevold, C., Toft‐Hansen, H., & Nielsen, C. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126481 · Cited by 14
Salardi, S., Porta, M., Maltoni, G., Bassi, M., Minuto, N., d’Annunzio, G., Baltatescu, T., Ariaudo, M., Zucchini, S., Levantini, G., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14438 · Cited by 10
“Duration of disease and poor glycaemic control are among the strongest risk factors for the development of microvascular complications in type 1 diabetes (T1D), especially diabetic retinopathy (DR).(1-5) Advances in glucose-lowering treatment may have led to improved”
BackgroundGlycemic Targets in Diabetes Care: Emerging Clarity after Accord.
Buse, J. B. (2015) · Europe PMC (PubMed Central) · Cited by 15
Nikolaidou, B., Triantafyllou, Α., Anyfanti, P., Gavriilaki, E., Lazaridis, A. A., Dolgyras, P., Gavriilaki, M., Stoimeni, A., Mastrogiannis, Κ., Trakatelli, C., et al. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf004 · Cited by 9
“Similarly, the VISS study (Vascular Diabetic Complications in Southeast Sweden) demonstrated that long-term weighted average HbA 1c was associated with the onset of severe retinopathy in type 1 DM. 29 The above reasons explain why no difference was found between groups, regarding retinopathy indicators at this early s…”
InfluentialAtkinson, M. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00032-0 · Cited by 16
Improving access to HbA1c in sub-Saharan Africa (IA3) cohort: cohort profile
Balde, N. M., Camara, A., Sobngwi-Tambekou, J. L., Balti, E. V., Tchatchoua, A. P., Fezeu, L., Limen, S., Ngamani, S., Ngapout, S., Kengne, A. P., et al. (2017) · Pan African Medical Journal · doi:10.11604/pamj.2017.27.275.10270 · Cited by 8
“Although adequate for the main study purpose the study sample may actually be rather small to investigate major outcomes such as diabetes-associated complications or mortality [9-11].”
BackgroundBolotskaya, L. L., Bessmertnaya, E. G., Shestakova, M. V., Шамхалова, М. Ш., Nikankina, L. V., Ilyin, А. V., Glek, I. S., Zolotukhin, A. V., & Dedov, I. I. (2017) · Terapevticheskii arkhiv · doi:10.17116/terarkh2017891017-21 · Cited by 11
“Nordwall M et al. Impact of HbA1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy: the VISS study (Vascular Diabetic Complications in Southeast Sweden).”
InfluentialZhang, L., Zhao, H., & Chen, B. (2019) · International Journal of Ophthalmology · doi:10.18240/ijo.2019.07.03 · Cited by 10
Mangla, P., Gupta, S., Chopra, A., Bhatia, V., Vishwakarma, R., & Asthana, P. (2020) · The Indian Journal of Pediatrics · doi:10.1007/s12098-020-03227-w · Cited by 8
Al‐Sofiani, M. E., AlMesned, R. K., Bafadel, M., Alguwaihes, A. M., & Alfadda, A. A. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.06.002 · Cited by 8
[Crown lengthening by orthodontic extrusion. Principles and technics].
Sabri, R. (1989) · PubMed · Cited by 12
Watso, J. C., Robinson, A. T., Singar, S., Cuba, J. N., & Koutnik, A. P. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00694.2023 · Cited by 8
Microvascular diabetes complications in a specialist young adult diabetes service
Melvin, A., Redahan, L., Hatunic, M., & McQuaid, S. (2018) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-018-1827-9 · Cited by 7
Ahmedani, M. Y., Fawwad, A., Shaheen, F., Tahir, B., Waris, N., & Basit, A. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i3.224 · Cited by 12
The epidemiology of type 1 diabetes: Helping to fit the puzzle pieces
Forga, L. (2015) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2015.02.011 · Cited by 7
Hatz, K. B., Minder, A. E., Lehmann, R., Drescher, T., Gerendas, B. S., Schmidt-Erfurth, U. M., Kaider, A., Prünte, C. F., & Zulewski, H. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.01.016 · Cited by 7
Huang, F., Wu, X., Xie, Y., Liu, F., Li, J., Li, X., & Zhou, Z. (2020) · Trials · doi:10.1186/s13063-020-04835-9 · Cited by 7
Neubauer‐Geryk, J., Wielicka, M., Myśliwiec, M., Zorena, K., & Bieniaszewski, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063190 · Cited by 6
“Studies have also demonstrated that rats with diabetes have reduced levels of circulating endothelial progenitor cells as a result of neuropathy, a phenomenon thought to precede the development of diabetic retinopathy [10–12].”
BackgroundCarral, F., Tomé, M., Alba, J. J. F., Zaldivar, A. P., Expósito, C., Jiménez, A. I., García, C., & Ayala, C. (2020) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2020.07.009 · Cited by 7
McCarroll, Z., Townson, J. K., Pickles, T., Gregory, J. W., Playle, R., Robling, M. R., & Hughes, D. A. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043523 · Cited by 7
Sebastián‐Valles, F., de Arenas‐Arroyo, S. N., Simó‐Servat, O., Simó, R., Painter, H., Martín, J. A. A., Navas-Moreno, V., Marazuela, M., Martínez‐Vizcaíno, V., & Alfonso, J. M. (2025) · BMC Medicine · doi:10.1186/s12916-025-04559-0 · Cited by 7
“They also tend to have lower treatment adherence and chronically suboptimal glycemic control [133], all of which are well-established contributors to the development and progression of DR.”
Xu, J., Xue, Y., Chen, Q., Han, X., Cai, M., Tian, J., Jin, S., & Lu, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.928825 · Cited by 8
Real-life data of hypoglycemic events in children and adolescents with type 1 diabetes
Hill, H., Klaar, P., & Espes, D. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003485 · Cited by 5
Chemlal, H., Bournine, L., Mimoune, S., Boufeniche, S., Beddou, L., Bensalem, S., & Iguer‐Ouada, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108543 · Cited by 6
Neubauer‐Geryk, J., Wielicka, M., Myśliwiec, M., Zorena, K., & Bieniaszewski, L. (2023) · Biomedicines · doi:10.3390/biomedicines11102857 · Cited by 5
“Nordwall et al. [77] showed that a weighted average of HbA1c measured levels, obtained over a long period of time starting at the time of diagnosis, is significantly associated with the development of complications in type 1 diabetes.”
BackgroundPaes, V. M., Charalampopoulos, D., Khanolkar, A. R., Taylor-Robinson, D. C., Viner, R., Edge, J., Stephenson, T. J., & Amin, R. (2015) · Systematic Reviews · doi:10.1186/s13643-015-0146-8 · Cited by 5
“Other studies have also suggested the beneficial effects of early glycaemic control in preventing future complications [36, 37].”
ResultMRI tracking of autologous pancreatic progenitor-derived insulin-producing cells in monkeys
Zou, C., Lu, Y., Teng, X., Wang, S.-Y., Sun, X., Huang, F., Shu, G., Huang, X., Guo, H.-W., Chen, Z.-G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02775-0 · Cited by 4
Cooper, M. N., de Bock, M. I., Carter, K. W., de Klerk, N. H., Jones, T. W., & Davis, E. A. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.11.022 · Cited by 5
O’Daffer, A., Yi‐Frazier, J. P., Roberts, A. J. C., Lowry, S., Pihoker, C., Hirsch, I. B., Weaver, K. W., Zenno, A., & Malik, F. S. (2024) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsae085 · Cited by 7
Sebastián‐Valles, F., García-Artacho, E., Santiago-Redondo, A., Castañar, S. G., Tapia-Sanchiz, M. S., Amar, S., Navas-Moreno, V., Palacios, E. P. L., Martín, J. A. A., & Marazuela, M. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251403567 · Cited by 5
Fisher, C., Williman, J. A., Burnside, M. J., Davies, H., Jefferies, C., Paul, R. G., Wheeler, B. J., & de Bock, M. I. (2024) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.16566 · Cited by 4
“6 Outsourcing of this expertise is not conducive to a multidisciplinary approach and fails to facilitate cohesive teamwork and consistent messaging to patients and their families.”
BackgroundMiele, F., Clementi, S., Gennaro, R., Nicolao, I., Romanelli, T., Speese, K., & Piras, E. M. (2019) · JMIR Diabetes · doi:10.2196/11343 · Cited by 6
“In the medium-to-long term, patients with poorly controlled diabetes may develop serious health issues, such as cardiovascular diseases [46,47], retinopathies [48,49], or renal diseases [50,51].”
BackgroundHealth economic evaluation of home and hospital-based care in T2D patients on insulin therapy
Janati, A., Sarabchian, M. A., Mohaghegh, B., Aghmohamadzadeh, N., Seyedin, H., Gholizadeh, M., & Hasanpoor, E. (2017) · Ethiopian Journal of Health Sciences · doi:10.4314/ejhs.v27i6.10 · Cited by 6
“reported a significant decrease in HbA1c in the experimental group (21), but with a nurse-coaching strategy undertaken by Whittemore et al.”
MethodDIABETIC RETINOPATHY: AN INCLUSIVE REVIEW ON CURRENT TREATMENT AND MANAGEMENT APPROACHES
Jyothi, S. L., & Vishal Gupta, N. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11i11.26949 · Cited by 4
Advantages from “do-it-yourself” loops among children and adolescents in Varna’s Diabetes Center
Bazdarska, Y., Iotova, V., Mladenov, V., Boyadzhiev, V., Stoycheva, R., Galcheva, S., & Bocheva, Y. (2020) · Scripta Scientifica Medica · doi:10.14748/ssm.v51i3.6515 · Cited by 6
“abetes mellitus (T1DM) (5-8) as well as episodes of acute severe hypoglycaemia and diabetic ketoacidosis (8,9).”
BackgroundPazzagli, L., Möllsten, A., & Waernbaum, I. (2017) · Annals of Epidemiology · doi:10.1016/j.annepidem.2017.07.003 · Cited by 6
Hector, S. M., Thulesius, H. O., Landin‐Olsson, M., Hillman, M., & Melin, E. O. (2023) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2023-001314 · Cited by 4
Serdiuk, A. V. (2024) · Archive of Ukrainian Ophthalmology · doi:10.22141/2309-8147.12.2.2024.377 · Cited by 7
Metadata
- Authors
- Nordwall, M., Abrahamsson, M., Dhir, M., Fredrikson, M., Ludvigsson, J., & Arnqvist, H. J.
- Affiliations
- Linköping University (SE)
- Corresponding author
- Nordwall, Maria
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-12-15
- Volume
- 38
- Issue
- 2
- Pages
- 308-315
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2095970617
- Cited by
- 161
- References
- 41
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 15 · 2023: 13 · 2022: 16 · 2021: 8 · 2020: 19 · 2019: 13 · 2018: 16 · 2017: 20 · 2016: 15 · 2015: 13
- FWCI
- 12.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- HbA1c, type 1 diabetes, proliferative diabetic retinopathy, diabetic nephropathy, macroalbuminuria, microvascular complications, glycemic targets, long-term glycemic control
- MeSH terms
- Adolescent, Adult, Aged, Child, Diabetes Mellitus, Type 1, Diabetic Angiopathies, Diabetic Nephropathies, Diabetic Retinopathy, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Male, Middle Aged, Sweden, Incidence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.